These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20235885)

  • 1. mTOR signaling in lymphangioleiomyomatosis.
    Kristof AS
    Lymphat Res Biol; 2010 Mar; 8(1):33-42. PubMed ID: 20235885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphangioleiomyomatosis: Current understanding and potential treatments.
    Moir LM
    Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
    Gao N; Zhang T; Ji J; Xu KF; Tian X
    Orphanet J Rare Dis; 2018 Aug; 13(1):134. PubMed ID: 30107845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis.
    Yu J; Henske EP
    Lymphat Res Biol; 2010 Mar; 8(1):43-9. PubMed ID: 20235886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).
    Kwiatkowski DJ
    Lymphat Res Biol; 2010 Mar; 8(1):51-7. PubMed ID: 20235887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
    Yates DH
    Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.
    Kristof AS; You Z; Han YS; Giaid A
    Peptides; 2010 Aug; 31(8):1511-6. PubMed ID: 20433884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
    El-Chemaly S; Goldberg HJ; Glanville AR
    Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
    Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
    Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphangioleiomyomatosis: New Treatment Perspectives.
    Radzikowska E
    Lung; 2015 Aug; 193(4):467-75. PubMed ID: 25980593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracrine steroid production and mammalian target of rapamycin pathways in pulmonary lymphangioleiomyomatosis.
    Adachi K; Miki Y; Saito R; Hata S; Yamauchi M; Mikami Y; Okada Y; Seyama K; Kondo T; Sasano H
    Hum Pathol; 2015 Nov; 46(11):1685-93. PubMed ID: 26298231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
    Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
    Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional consequences of mTOR inhibition.
    Sudarsanam S; Johnson DE
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LAM cells biology and lymphangioleiomyomatosis.
    Grzegorek I; Drozdz K; Podhorska-Okolow M; Szuba A; Dziegiel P
    Folia Histochem Cytobiol; 2013; 51(1):1-10. PubMed ID: 23690211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis.
    Evans JF; Obraztsova K; Lin SM; Krymskaya VP
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.
    Huang YL; Chen PR; Lai YJ; Hsu HH
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension.
    Mejias M; Garcia-Pras E; Gallego J; Mendez R; Bosch J; Fernandez M
    J Hepatol; 2010 Apr; 52(4):529-39. PubMed ID: 20206401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling.
    Al Mahi N; Zhang EY; Sherman S; Yu JJ; Medvedovic M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.